怀孕期间喘的可治疗特征:呼吁转向基于精度的管理方法
Esha Joshi1,2, Peter G Gibson1,2,3, Vanessa M McDonald1,2,4
1School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
概括
怀孕期间的喘需要谨慎管理,以预防并发症. 可治疗特征方法为患有喘的孕妇提供了个性化的策略,解决诸如肥胖和坚持等因素,以改善结果.
科学领域:
- 肺部医学 肺部医学
- 产科 产科 产科 产科 产科
- 精准医学是一门精准的医学.
背景情况:
- 喘是怀孕期间常见的慢性疾病,对母亲和胎儿都有风险.
- 无法预测的喘恶化会导致不良的周产期结果,包括早产和低出生体重.
- 有效控制喘和预防喘恶化是怀孕期间控制喘的关键目标.
研究的目的:
- 审查当前对怀孕中喘的理解.
- 探索可治疗的特征模式来管理复杂的呼吸道疾病.
- 评估可治疗性状的适用性对于患有喘的孕妇.
主要方法:
- 关于怀孕中喘和可治疗特征范式的文献综述.
- 对患有喘的孕妇可治疗特征的流行率的分析.
- 关于将可治疗的特征纳入怀孕期间喘管理的讨论.
主要成果:
- 患有喘的孕妇经常表现出可治疗的特征,如肥胖,心理健康状况和症状感知能力差.
- 这些特征是可测量的,易于干预的,突出了个性化管理的潜力.
- 可治疗特征的方法与患有喘的孕妇的复杂需求相吻合.
结论:
- 可治疗特征范式提供了一个有前途的,个性化的方法,在怀孕期间治疗喘.
- 整合可治疗的特征可以优化喘控制,改善母亲和胎儿的结果.
- 这种精准医学方法需要进一步的研究和临床整合.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
411
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
411
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Leukotriene Modifiers
315
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
315


